Spots Global Cancer Trial Database for Study of Gefitinib Retreatment in Non-Small Cell Lung Cancer (NSCLC)
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Study of Gefitinib Retreatment in Non-Small Cell Lung Cancer (NSCLC)
Official Title: Retreatment of Gefitinib in the Patients With Non-small Cell Lung Cancer (NSCLC) Previously Responded to Gefitinib A Single Arm, Open Label, Phase II Study
Study ID: NCT00824746
Conditions
Interventions
Study Description
Brief Summary: A single arm, open label, prospective, phase II trial of Gefitinib retreatment for the advanced or metastatic (IIIb and IV) NSCLC patients who previously responded to gefitinib And progressive disease should be observed with at least one prior regimen following previous gefitinib failure. Primary endpoint * to assess Disease Control Rate (Remission + Stable disease) Secondary endpoints * to assess the progression free survival
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Chonnam National University Hwasun Hospital, Hwasun-gun, Jeonnam, Korea, Republic of
Contact Details
Name: Young-Chul Kim, MD, PhD
Affiliation: Chonnam National University Hospital
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
